Translational Oncolytic Virotherapy

  • Author: Ann-Christin Hau
  • Published: 04 April 2017
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Nature Communications/Nature Publishing Group
thumbnail image: Translational Oncolytic Virotherapy

Oncolytic viral therapy is an up-and-coming anti-tumor therapeutic approach that adopts oncolytic viruses (OVs) to kill cancer cells. Here, one major obstacle is to guarantee patient safety during OV treatment. This issue can be overcome by establishing oncoselectivity of the treatment, i.e., the selective elimination of cancer cells while rendering healthy tissue unaffected.

Raúl Méndez and Cristina Fillat, Institut d’Investigacions Biome`diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, and colleagues made use of the recent discovery that many different types of cancer cells reactivate programs in control of mRNA translation via cytoplasmic polyadenylation element-binding proteins (CPEBs). In general, CPEBs are known to regulate mRNA translation through cis-binding of the cytoplasmic polyadenylation element (CPE) present in mRNAs 3'-untranslated region (3'-UTR). To this end, the scientists inserted a CPE regulatory sequences in the 3′ UTR of the E1A viral gene supposedly activating E1A expression in cancer cells while promoting its translational repression in normal tissues. Several cell lines reflecting pancreatic adenocarcinomas, colorectal carcinomas, and malignant brain tumors were validated to upregulate CPE-mediated E1A expression and thus viral activity dependent on high levels of CBEP4 typical for those tumors. In contrast to control cell lines, e.g., human embryonic kidney (HEK), retinal pigment epithelial (RPE), human hepatocytes, and fibroblasts maintained high levels of CBEP1 mediating repression of CPE-containing mRNAs.

In vivo proof of principle for this methodology was provided using nude mice carrying subcutaneous pancreatic tumors and demonstrated reduced viral toxicity in healthy tissues and sustained oncolytic potency.


Article Views: 1668

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from, please contact us first for permission. more

CONNECT: on Facebook on Twitter on YouTube on LinkedIn Sign up for our free newsletter

A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH